FDA said to have named Katherine Szarama as acting CBER chief
Source: SeekingAlpha
2026-05-01 11:20:07 ET
More on Pfizer, GSK, etc.
- Pfizer: Why You Should Double Down Into Q1
- GSK plc (GSK) Q1 2026 Earnings Call Transcript
- GSK plc 2026 Q1 - Results - Earnings Call Presentation
- Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK
- Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
Read the full article on Seeking Alpha
For further details see:
FDA said to have named Katherine Szarama as acting CBER chief
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
